Cancer Research UK
has announced that it has initiated a clinical trial that will allow patients
taking part to stay at home and take the medication in tablet form.
Clinical trials are vital in the development of new cancer treatment, but are often
hindered by the commitment issues, as patients usually need to stay in
hospitals for long periods of time.
"It's great news that we're able to run a trial of this exciting drug as a
tablet which will be a much more convenient and comfortable way to receive the treatment,"
said professor Ruth Plummer, the trial's chief investigator.
She explained that making the drug available in tablet form allowed
participants to regain some semblance of normality, as they would not be hooked
up to a drip.
Patients will test the effectiveness of Rucaparib, a PARP inhibitor, which has
so far displayed promising results when used to treat breast cancer.
Scientists funded by the charity recently discovered that oestrogen
concentrations are linked to the likelihood of a breast cancer relapse.
© Adfero Ltd
Cancer treatment news : 13 January 2012
